New Approaches to SCLC Therapy: From the Laboratory to the Clinic is a research paper published in Journal of Thoracic Oncology (2020). On theSindex it has a DataRank of 5.4. It has been cited 178 times, with 135 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.778
From this paper's citation signal
Citation Network Contribution
4.6
From 109 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 135 citers.
National Institutes of Health
Grant: R01 CA207295
National Institutes of Health
Grant: R01 CA213448
National Institutes of Health
Grant: R21 CA216504
National Institutes of Health
Grant: U01 CA213338
National Institutes of Health
Grant: U01 CA213359
National Institutes of Health
Grant: U01 CA231844
National Institutes of Health
Grant: U24 CA213274
Victorian Cancer Agency
Grant: MCRF18003
Pfizer
Grant: APP1138275
National Health and Medical Research Council
Grant: APP1159955
NCI NIH HHS
Grant: K08 CA222657
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: R01 CA181449
NCI NIH HHS
Grant: R35 CA231997
Cancer Research UK
Grant: 29420
Cancer Research UK
Grant: 29569
NCI NIH HHS
Grant: U01 CA213273
Cancer Research UK
Grant: 19278
NCI NIH HHS
Grant: R00 CA226353
Cancer Research UK
Grant: 20465
NCI NIH HHS
Grant: K99 CA201618
NCI NIH HHS
Grant: U01 CA231851
NCI NIH HHS
Grant: U01 CA242919
NCI NIH HHS
Grant: U54 CA217450
Agios Pharmaceuticals
Amgen
University of Texas Southwestern Medical Center
AbbVie
Bayer Fund
Karolinska Institutet
Takeda Oncology
AstraZeneca
Cold Spring Harbor Laboratory
Daiichi-Sankyo
Merck
Aeglea BioTherapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
National Cancer Institute
Roche
ANGLE
Astex Pharmaceuticals
Janssen Pharmaceuticals
Merck KGaA
Meso Scale Diagnostics
TG Therapeutics
Eli Lilly and Company
International Association for the Study of Lung Cancer
Kyowa Hakko Kirin
GlaxoSmithKline
Astellas Pharma US
Celgene
Novartis
FWCI
9.19
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung cancer
Additional file 1 of AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung cancer